GRIK1

Glutamate receptor ionotropic, kainate 1 · P39086 · GRIK1 on Sugi Atlas →

73,881 patent compounds predicted against GRIK1, 42,565 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL30895	0.69	12/20
SCHEMBL71719	0.69	12/20
Hydrochloric Acid (SCHEMBL74585)	0.66	12/20
Aspartic Acid (SCHEMBL135731)	0.57	11/20
Leucine (SCHEMBL122270)	0.44	11/20
Leucine (SCHEMBL122271)	0.44	11/20
Leucine (SCHEMBL138874)	0.41	11/20
Lobenzarit (SCHEMBL7935)	0.61	10/20
Leucine (SCHEMBL175940)	0.52	9/20
Leucine (SCHEMBL175941)	0.52	9/20
SCHEMBL151676	0.48	9/20
Asparagine (SCHEMBL15460)	0.54	8/20
Asparagine (SCHEMBL38379)	0.54	8/20
Asparagine (SCHEMBL150535)	0.54	8/20
SCHEMBL59095	0.49	8/20
SCHEMBL175205	0.57	7/20
Asparagine (SCHEMBL50254)	0.52	7/20
Asparagine (SCHEMBL50255)	0.52	7/20
Leucine (SCHEMBL67322)	0.50	7/20
SCHEMBL60226	0.49	7/20

Clinical trials — most relevant to GRIK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial	PHASE2/PHASE3	NOT_YET_RECRUITING
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders	PHASE3	RECRUITING
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease	PHASE3	COMPLETED
Defining the Clinical Role of Topiramate in the Treatment of Alcohol Dependence in Australia	PHASE3	UNKNOWN
Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD	PHASE2	RECRUITING
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
Effects of Direct Transcranial Current Stimulation on Central Neural Pain Processing in Fibromyalgia	PHASE1/PHASE2	COMPLETED
Brain Imaging, Genetics and Treatment for Major Depression	PHASE1	WITHDRAWN
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial	PHASE1	COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response	PHASE1	RECRUITING
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203	PHASE1	COMPLETED
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression	PHASE1	RECRUITING
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy	nan	UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome	nan	UNKNOWN
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients	nan	COMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
(GluEsk) Glutamate and Esketamine	nan	COMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
Effect of D-cycloserine on Extinction of Fear Conditioning	nan	COMPLETED
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions	nan	COMPLETED
7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis	nan	RECRUITING
Mechanisms of Human Plasticity in the Human System	nan	COMPLETED
Acamprosate: Genes Associated With Response	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GRIK1 binder may also engage these)

Protein	Name	Similarity
Q38PU4	—	1.000	Q38PU4 →
P42260	—	1.000	P42260 →
B1AS29	—	1.000	B1AS29 →
Q38PU2	—	1.000	Q38PU2 →
P42264	—	1.000	P42264 →
P39087	—	1.000	P39087 →
Q91755	—	1.000	Q91755 →
Q38PU3	—	1.000	Q38PU3 →
GRIK2	Glutamate receptor ionotropic, kainate 2	0.999	landscape →
Q60934	—	0.999	Q60934 →
Q9Z2W8	—	0.999	Q9Z2W8 →
GRIK3	Glutamate receptor ionotropic, kainate 3	0.999	landscape →
P22756	—	0.998	P22756 →
GRIA2	Glutamate receptor 2	0.997	landscape →
A0A2R8QF68	—	0.997	A0A2R8QF68 →
GRIA4	Glutamate receptor 4	0.996	landscape →
Q5R4M0	—	0.996	Q5R4M0 →
P23819	—	0.995	P23819 →
P26591	—	0.995	P26591 →
Q38PU5	—	0.994	Q38PU5 →
P19492	—	0.994	P19492 →
P19491	—	0.993	P19491 →
GRIA1	Glutamate receptor 1	0.993	landscape →
Q38PU7	—	0.993	Q38PU7 →
P19493	—	0.992	P19493 →
GRIA3	Glutamate receptor 3	0.992	landscape →
P19490	—	0.992	P19490 →
Q38PU8	—	0.992	Q38PU8 →
Q38PU6	—	0.991	Q38PU6 →
Q9Z2W9	—	0.991	Q9Z2W9 →